Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.83 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 18
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 18
Join SI Premium – FREE
Baird maintains a 'Neutral' on Biogen (NASDAQ: BIIB) price target raised from $130 to $135.
Analyst, Christopher J. Raymond, said, "BIIB shares are taking a breather today (-1% vs. NBI +0.5%) in response to a Q112 revenue/earnings miss and lukewarm FY12 guidance-raise. That said, we think near-term the stock can continue to work higher on expectations for key 2H12 pipeline events. However, with already huge BG12 launch expectations built-in, and Hemophilia and ALS data readouts more high-risk, we think the stock’s premium valuation makes it more vulnerable should any of these disappoint."
Raises FY13 EPS estimate from $7.30 to $7.63.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $134.01 yesterday.
Analyst, Christopher J. Raymond, said, "BIIB shares are taking a breather today (-1% vs. NBI +0.5%) in response to a Q112 revenue/earnings miss and lukewarm FY12 guidance-raise. That said, we think near-term the stock can continue to work higher on expectations for key 2H12 pipeline events. However, with already huge BG12 launch expectations built-in, and Hemophilia and ALS data readouts more high-risk, we think the stock’s premium valuation makes it more vulnerable should any of these disappoint."
Raises FY13 EPS estimate from $7.30 to $7.63.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $134.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quanterix Corp. (QTRX) PT Lowered to $3 at Canaccord
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
- Enhanced Group Inc. (ENHA) PT Lowered to $5 at Canaccord
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Robert W Baird, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
